Giulia KennedyPhD
The Lancet Respiratory Medicine · 2019

Use of a molecular classifier to identify usual interstitial pneumonia in conventional transbronchial lung biopsy samples: a prospective validation study

Ganesh Raghu, Kevin R Flaherty, David J Lederer, David A Lynch, Thomas V Colby, Jeffrey L Myers, Steve D Groshong, Brandon T Larsen, Jonathan H Chung, Mark P Steele, Sadia Benzaquen, Karel Calero, Amy H Case, Gerard J Criner, Steven D Nathan, Navdeep S Rai, Murali Ramaswamy, Lars Hagmeyer, J Russell Davis, Umair A Gauhar, Daniel G Pankratz, Yoonha Choi, Jing Huang, P Sean Walsh, Hannah Neville, Lori R Lofaro, Neil M Barth, Giulia C Kennedy, Kevin K Brown, Fernando J Martinez

Co-authorverifiedPulmonary genomic classifiers
Journal
The Lancet Respiratory Medicine · vol. 7 · no. 6 · pp. 487-496
Published
Jun 2019

Synopsis

The prospective clinical validation of the Envisia Genomic Classifier, which had a high positive predictive value for identifying usual interstitial pneumonia in conventional transbronchial lung biopsy samples and could be used in place of surgical lung biopsy to confirm a diagnosis of idiopathic pulmonary fibrosis. Veracyte announced the publication on April 1, 2019, quoting Kennedy as chief scientific officer and chief medical officer and an author. She is twenty-eighth of thirty authors.

In the career genome

  • VeracyteChapter 06 · Strand A · Company
    Veracyte, Inc.

    Veracyte

    Chief Scientific Officer; Chief Medical Officer from 2018; Global Chief Scientific Officer and Chief Medical Officer from 2022

    APR 2008 – DEC 2022
  • VeracyteChapter 09 · Strand B · Research
    Veracyte, Inc.

    Percepta and Envisia

    Chief Scientific Officer and Chief Medical Officer, Veracyte

    APR 2015 – APR 2024